SNIPR Biome leverages CRISPR-Cas technology to develop microbial medicines for precision killing of bacteria and gene modification, addressing critical infectious diseases like antibiotic-resistant infections in cystic fibrosis and hematologic cancers. The company focuses on selective, ultra-rapid bacterial eradication while preserving the patient’s microbiome, with a pipeline targeting pathogens of high importance, including Pseudomonas aeruginosa and antibiotic-resistant bacteria.
Bevorzugte Reifephase für die erste Finanzierung.
CRISPR-based microbial interventions, precision killing of bacteria, and gene modification for therapeutic applications targeting antimicrobial resistance and infectious diseases
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
